Pan Boyu, Liu Ling, Wang Xiaofeng, Wang Runfang, Liu Zeyang, Li Xiaoyan, Jin Bao, Zhang Jie, Li Rui, Liu Liren, Wu Chunnuan
Department of Molecular Pharmacology, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China.
Department of Physics, School of Basic Medicine, Shanxi Medical University, Taiyuan, 030001, Shanxi, China.
Chin Med. 2025 Aug 25;20(1):133. doi: 10.1186/s13020-025-01186-y.
Piper longum demonstrates significant therapeutic potential against gastric cancer (GC), but its underlying mechanisms remain incompletely understood. This study aimed to establish a comprehensive multi-omics framework to elucidate Piper longum's anti-cancer mechanisms.
We integrated in vivo experiments, metabolomics, gut microbiota analysis, mass spectrometry, and network pharmacology to investigate Piper longum's effects. In vivo studies assessed its dose-dependent inhibition of GC growth compared to standard chemotherapy (L-OHP + 5-FU). Metabolomics identified altered lipid metabolism pathways, while gut microbiota analysis evaluated its impact on microbial composition. Piperine was identified as the key active compound, and ACOT1 was pinpointed as a critical molecular target through integrated analysis.
Piper longum significantly suppressed gastric cancer (GC) growth in a dose-dependent manner, with high-dose treatment demonstrating superior efficacy compared to conventional chemotherapy (L-OHP + 5-FU). Metabolomic analysis revealed that its anti-cancer mechanism primarily involves the reprogramming of lipid metabolism pathways in GC cells, while gut microbiota assessment confirmed that it modulates intestinal flora composition without compromising microbial diversity, supporting its favorable safety profile. Mass spectrometry identified piperine as the key bioactive compound, and integrated metabolomics and network pharmacology further pinpointed ACOT1 as a critical molecular target, which interacts with piperine that confirmed by CETSA. Notably, high ACOT1 expression was associated with poor prognosis in GC patients, underscoring its therapeutic relevance.
This study elucidates Piper longum's "component-target-pathway" mechanism in GC treatment, highlighting piperine-ACOT1-de novo lipogenesis regulatory pathway as a critical axis. Additionally, it establishes a robust multi-omics framework for evaluating traditional medicine efficacy, providing a theoretical foundation for Piper longum's clinical application in GC therapy.
荜茇对胃癌(GC)显示出显著的治疗潜力,但其潜在机制仍未完全明确。本研究旨在建立一个全面的多组学框架,以阐明荜茇的抗癌机制。
我们整合了体内实验、代谢组学、肠道微生物群分析、质谱和网络药理学来研究荜茇的作用。体内研究评估了与标准化疗(L-OHP + 5-FU)相比,其对GC生长的剂量依赖性抑制作用。代谢组学确定了脂质代谢途径的改变,而肠道微生物群分析评估了其对微生物组成的影响。通过综合分析,确定胡椒碱为关键活性化合物,ACOT1为关键分子靶点。
荜茇以剂量依赖性方式显著抑制胃癌(GC)生长,高剂量治疗显示出比传统化疗(L-OHP + 5-FU)更好的疗效。代谢组学分析表明,其抗癌机制主要涉及GC细胞中脂质代谢途径的重编程,而肠道微生物群评估证实它可调节肠道菌群组成,同时不影响微生物多样性,支持其良好的安全性。质谱鉴定胡椒碱为关键生物活性化合物,综合代谢组学和网络药理学进一步确定ACOT1为关键分子靶点,CETSA证实其与胡椒碱相互作用。值得注意的是,GC患者中ACOT1高表达与预后不良相关,突出了其治疗相关性。
本研究阐明了荜茇在GC治疗中的“成分-靶点-途径”机制,强调胡椒碱-ACOT1-从头脂肪生成调节途径为关键轴。此外它建立了一个强大的多组学框架来评估传统药物的疗效,为荜茇在GC治疗中的临床应用提供了理论基础。